Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Narayana Hrudayalaya Limited (NH.NS)
Bengaluru, IN
Narayana Hrudayalaya Limited, established in 2000 and headquartered in Bengaluru, India, operates as a prominent provider of medical and healthcare services. The company oversees and manages a diverse range of healthcare facilities, encompassing hospitals, clinics, health centers, and nursing homes. It delivers specialized care across a comprehensive spectrum of medical disciplines, including cardiology, cardiac surgery, nephrology, urology, neurology, neuro-surgery, endocrinology, orthopedics, internal medicine, obstetrics, gynecology, pediatrics, neonatology, gastroenterology, and oncology. As of June 30, 2022, Narayana Hrudayalaya maintained an extensive network that included 19 owned or operated hospitals, 2 managed hospitals, 4 heart centers, and 18 clinics and information centers throughout India, complemented by an international presence with one hospital in the Cayman Islands. Additionally, the company extends its expertise through healthcare consultancy services, which involve the licensing of its ERP solutions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.51% | -1.58% | +6.96% | +2.16% | -3.85% | -0.03% | +6.44% | +124.09% | +339.09% | +486.75% | +461.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+44.0% ★ Q1'26: +75.8% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+2.1% Q1'26: +14.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+12.9% ★ Q1'26: +15.9% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+15.4% ★ Q1'26: +14.8% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+13.6% ★ Q1'26: +16.0% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×3.52× Q1'26: 2.73× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 10 Rev. Ana. 8 EPS Ana. |
Mar 2027 10 Rev. Ana. 9 EPS Ana. |
Mar 2028 10 Rev. Ana. 9 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16.18B
est: 16.09B (+0.6%)
|
18.88B
est: 18.73B (+0.8%)
|
22.94B
est: 22.44B (+2.2%)
|
28.74B
est: 28.66B (+0.3%)
|
31.36B
est: 31.38B (-0.1%)
|
25.84B
est: 25.34B (+2.0%)
|
37.01B
est: 36.65B (+1.0%)
|
45.30B
est: 45.18B (+0.3%)
|
48.90B
est: 51.26B (-4.6%)
|
54.83B
est: 55.50B (-1.2%)
|
74.29B
71.72B – 76.82B
+33.9% YoY
|
99.19B
88.57B – 107.40B
+33.5% YoY
|
111.78B
104.68B – 124.93B
+12.7% YoY
|
| EBITDA |
1.77B
est: 2.82B (-37.4%)
|
2.41B
est: 923.88M (+161.0%)
|
2.27B
est: 2.26B (+0.4%)
|
2.96B
est: 1.66B (+78.4%)
|
3.86B
est: 1.81B (+112.8%)
|
1.43B
est: 2.25B (-36.6%)
|
6.19B
est: 3.09B (+100.3%)
|
9.31B
est: 3.37B (+176.3%)
|
11.02B
est: 10.59B (+4.1%)
|
12.28B
est: 11.41B (+7.6%)
|
15.34B
14.81B – 15.87B
+34.4% YoY
|
20.48B
18.29B – 22.18B
+33.5% YoY
|
23.08B
21.62B – 25.80B
+12.7% YoY
|
| EBIT |
1.03B
est: 2.16B (-52.2%)
|
1.64B
est: 1.04B (+57.3%)
|
1.29B
est: 1.77B (-27.3%)
|
1.62B
est: 1.45B (+12.2%)
|
2.48B
est: 1.65B (+50.0%)
|
68.65M
est: 1.99B (-96.5%)
|
4.81B
est: 2.73B (+76.5%)
|
7.67B
est: 2.97B (+158.2%)
|
9.12B
est: 8.43B (+8.2%)
|
10.03B
est: 9.09B (+10.3%)
|
12.22B
11.80B – 12.64B
+34.4% YoY
|
16.31B
14.57B – 17.67B
+33.5% YoY
|
18.39B
17.22B – 20.55B
+12.7% YoY
|
| Net Income |
212.32M
est: 203.10M (+4.5%)
|
830.53M
est: 249.56M (+232.8%)
|
513.47M
est: 985.88M (-47.9%)
|
591.69M
est: 641.96M (-7.8%)
|
1.19B
est: 657.87M (+80.8%)
|
-143.04M
est: 1.04B (-113.8%)
|
3.42B
est: 1.42B (+140.2%)
|
6.06B
est: 6.80B (-10.8%)
|
7.89B
est: 8.07B (-2.2%)
|
7.90B
est: 7.85B (+0.7%)
|
8.94B
8.21B – 9.66B
+13.9% YoY
|
11.65B
9.24B – 12.00B
+30.3% YoY
|
13.85B
11.29B – 14.52B
+18.9% YoY
|
| SGA |
1.09B
est: 668.48M (+63.7%)
|
1.23B
est: 7.75B (-84.1%)
|
1.53B
est: 6.86B (-77.7%)
|
1.84B
est: 9.13B (-79.9%)
|
1.50B
est: 10.53B (-85.8%)
|
1.12B
est: 8.45B (-86.7%)
|
1.39B
est: 11.59B (-88.0%)
|
1.77B
est: 12.63B (-86.0%)
|
2.14B
est: 1.68B (+27.1%)
|
2.41B
est: 18.06B (-86.7%)
|
2.44B
2.36B – 2.52B
-86.5% YoY
|
3.26B
2.91B – 3.53B
+33.5% YoY
|
3.67B
3.44B – 4.11B
+12.7% YoY
|
| EPS |
1.06
est: 1.00 (+6.0%)
|
4.10
est: 3.86 (+6.3%)
|
2.53
est: 3.63 (-30.3%)
|
2.92
est: 3.02 (-3.2%)
|
5.86
est: 5.72 (+2.4%)
|
-0.70
est: -1.95 (+64.1%)
|
16.85
est: 16.24 (+3.8%)
|
29.85
est: 28.20 (+5.9%)
|
38.68
est: 39.72 (-2.6%)
|
38.86
est: 38.92 (-0.1%)
|
43.92
40.44 – 47.58
+12.9% YoY
|
55.20
45.49 – 59.07
+25.7% YoY
|
65.14
55.60 – 71.52
+18.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Schwab Emerging Markets Equity ETF SCHE | 0.01% | 1.72M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.01% | 709.1K | 0.17% |
| 3 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.01% | 709.1K | 0.17% |
| 4 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.01% | 73.1K | 0.40% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 360.1K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 159.7K | 0.48% |
| 7 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.00% | 145.5K | 0.04% |
| 8 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 33.4K | 0.24% |
| 9 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 33.4K | 0.24% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 28.6K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Devi Prasad Shetty | Founder & Executive Chairman | 175M | — |
| Emmanuel Rupert | MD, Group Chief Executive Officer & Director | 92M | — |
| Viren Prasad Shetty | Executive Vice-Chairman and Senior Vice President of Strategy & Planning | 47M | male |
| Sandhya Jayaraman | Group Chief Financial Officer | 28M | female |
| Seshiah Sridhar | Group Company Secretary, Legal & Compliance Officer | 11M | male |
| R. Venkatesh | Group Chief Operating Officer | — | male |
| Kumar Krishnamurthy Venkateswaran | Group Head Information Technology & Chief Information Officer | — | male |
| Nishant Singh | Vice President of Finance, Mergers & Acquisitions and Investor Relations | — | male |
| Ashish Bajaj | Group Chief Marketing Officer | — | male |
| Sirshendu Mookherjee | Group Head of Human Resources | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NH.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
